Long-term Upadacitinib Safety in Moderate-to-Severe Atopic Dermatitis up to 7 Years: an Integrated Analysis with Over 9600 Patient-Years of exposure. (2026). SKIN The Journal of Cutaneous Medicine, 10(2), s727. https://doi.org/10.25251/evafb145